000513.SHE Livzon Pharmaceutical Group Inc
- Market cap
- CNY 26.6B
- P/E
- 16.5x
- P/B
- 1.95x
- ROE
- 13.2%
- Dividend yield
- 3.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000513.SHE undervalued?
Graham number000513.SHE trades 19.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Livzon Pharmaceutical Group Inc fundamental analysis
No fundamental analysis for Livzon Pharmaceutical Group Inc yet.
Livzon Pharmaceutical Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the ga…
Full company profileLivzon Pharmaceutical Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Livzon Pharmaceutical Group Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.65B | 8.53B | 8.86B | 9.38B | 10.5B | 12.1B | 12.6B | 12.4B | 11.8B | 11.9B | 9.76B |
| Gross Profit | 4.87B | 5.42B | 5.45B | 5.94B | 6.78B | 7.75B | 8.05B | 7.66B | 7.56B | 7.63B | 5.88B |
| Operating Income | 881M | 5.66B | 1.27B | 1.73B | 2.50B | 2.27B | 2.35B | 2.42B | 2.84B | 2.62B | 2.26B |
| EBITDA | 1.29B | 1.45B | 1.36B | 1.76B | 2.42B | 2.34B | 2.56B | 2.74B | 3.09B | 3.18B | 2.49B |
| Net Income | 784M | 4.43B | 1.08B | 1.30B | 1.71B | 1.78B | 1.91B | 1.95B | 2.06B | 2.02B | 1.72B |
| EPS | 0.89 | 4.77 | 1.16 | 1.39 | 1.83 | 1.90 | 2.04 | 2.10 | 2.24 | 2.27 | 1.93 |
| Balance Sheet | |||||||||||
| Total Assets | 10.5B | 15.9B | 17.4B | 18.0B | 20.6B | 22.4B | 24.9B | 25.0B | 24.5B | 24.0B | 23.2B |
| Total Liabilities | 3.42B | 4.66B | 5.69B | 5.70B | 6.95B | 8.06B | 9.93B | 10.3B | 9.55B | 8.20B | 9.11B |
| Shareholders' Equity | 6.51B | 10.8B | 10.7B | 11.2B | 12.1B | 13.0B | 13.9B | 14.0B | 13.9B | 13.9B | 13.0B |
| Cash & Short-term Investments | 2.07B | 7.43B | 8.60B | 8.87B | 9.98B | 9.33B | 10.5B | 11.4B | 10.9B | 10.9B | 7.25B |
| Total Debt | 325M | 663M | 1.50B | 1.36B | 1.92B | 2.69B | 3.61B | 3.48B | 3.93B | 3.85B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.28B | 1.32B | 1.27B | 1.77B | 2.16B | 1.90B | 2.77B | 3.25B | 2.98B | 3.18B | - |
| Capital Expenditure | 368M | 294M | 474M | 398M | 647M | 1.31B | 940M | 820M | 570M | 574M | 444M |
| Free Cash Flow | 911M | 1.02B | 793M | 1.37B | 1.51B | 593M | 1.83B | 2.43B | 2.41B | 2.60B | 2.88B |
| Ratios | |||||||||||
| ROE | 12.1% | 41.1% | 10.2% | 11.7% | 14.2% | 13.7% | 13.8% | 13.9% | 14.9% | 14.6% | 13.2% |
| ROA | 7.4% | 27.9% | 6.2% | 7.2% | 8.3% | 7.9% | 7.7% | 7.8% | 8.4% | 8.4% | 7.4% |
| Net Profit Margin | 10.3% | 51.9% | 12.2% | 13.9% | 16.3% | 14.7% | 15.1% | 15.7% | 17.4% | 17.0% | 17.6% |
| Debt to Equity | 0.05x | 0.06x | 0.14x | 0.12x | 0.16x | 0.21x | 0.26x | 0.25x | 0.28x | 0.28x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Livzon Pharmaceutical Group Inc dividends
- Dividend yield
- 3.69%
- Forward dividend
- 2.45 CNY
- Payout ratio
- 48.5%
- Ex-dividend date
- Oct 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 982M | 1.10 | 48.5% |
| 2024 | CNY 1.34B | 1.46 | 65.0% |
| 2023 | CNY 1.49B | 1.60 | 76.1% |
| 2022 | CNY 1.22B | 1.30 | 63.7% |
| 2021 | CNY 1.17B | 1.25 | 65.8% |
| 2020 | CNY 1.07B | 1.15 | 62.7% |
| 2019 | CNY 868M | 0.93 | 66.7% |
| 2018 | CNY 1.12B | 1.20 | 103.6% |
| 2017 | CNY 216M | 0.23 | 4.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jul 3, 2019.
Who owns Livzon Pharmaceutical Group Inc
- Insiders 44.90%
- Institutions 5.50%
- Public & others 49.60%
- Shares outstanding 588M
- Free float 461M
Livzon Pharmaceutical Group Inc company profile
- Company name
- Livzon Pharmaceutical Group Inc
- Ticker
- 000513.SHE
- ISIN
- CNE0000002Y8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Sep 16, 1993
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8,878
- Fiscal year end
- December
- Address
- Headquarters Building, Zhuhai, China, 519090
- Phone
- 86 75 6813 5888
- Website
- livzon.com.cn
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits. In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; influenza A/B virus antigen detection kits; and treponema pallidum antibody detection kits. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, stomatitis granules, biochemical and polypeptide APIs, and antibiotic APIs, as well as diagnostic equipment. Livzon Pharmaceutical Group Inc. was incorporated in 1985 and is headquartered in Zhuhai, China.
Livzon Pharmaceutical Group Inc management
10- Mr. Daping LiuPresident & Chairman of the Board · born 1987
- Mr. Yanggang TangExecutive Vice Chairman · born 1970
- Ms. Yongmei RanEmployee Representative Director & Assistant to the President · born 1984
- Ms. Liu NingCompany Secretary & Secretary to the Board · born 1983
- Ms. Yuxuan HuangVice President · born 1968
- Mr. Jun DuVice President · born 1978
- Mr. Xiao XuVice President · born 1978
- Mr. Sheng WangFinancial Controller, Head of Accounting Department & CFO · born 1982
- Dr. Jianing LiuChief Investment Officer & Head of BD Dept.
- Mr. Maolin WangGM of Legal & Compliance · born 1966